Search results
Accumulate MM Forgings; target of Rs 1410: CD Equisearch
CNBC Awaaz· 33 minutes agoCD Equisearch recommended accumulate rating on MM Forgings with a target price of Rs 1410 in its...
Sell Sobha; target of Rs 1714: Geojit Financial Services
CNBC Awaaz· 53 minutes agoGeojit Financial Services is bearish on Sobha has recommended sell rating on the stock with a target...
Ajmera Realty shares higher on Q1 sales, talks of '5x growth strategy' and strong pipeline
CNBC Awaaz· 1 hour agoThe company reported a robust 36 percent year-on-year increase in sales value, reaching Rs 306...
Bank of Baroda falls 4% on weakest deposit and advances growth in last 12 quarters
CNBC Awaaz· 1 hour agoDeposit as well as advances growth for Bank of Baroda slipped around 2 percent each in the...
Buy Asian Paints; target of Rs 3385: Sharekhan
CNBC Awaaz· 2 hours agoSharekhan is bullish on Asian Paints has recommended buy rating on the stock with a target price of Rs 3385 in its research report dated July 05, 2024.
Dabur stock jumps 4% on positive Q1 business update, upbeat demand trends
CNBC Awaaz· 3 hours agoDabur expects growth to accelerate in the coming months, particularly in rural markets, driven by a...
PC Jeweller stock locked in 10% upper circuit after PNB greenlights one time settlement proposal
CNBC Awaaz· 3 hours agoPC Jewellers' financial difficulties began in February 2023 when banks decided to recall loans...
Eicher, BHEL, and more: Kotak flags overvalued stocks amid profitability concerns, unrealistic...
CNBC Awaaz· 3 hours agoKotak Institutional Equities' latest report highlights companies with inflated market caps despite...
Nifty, Sensex fall on profit booking; banks slip, FMCG and pharma rally
CNBC Awaaz· 4 hours agoAt about 9:25 am, the Sensex was down 0.21 percent at 79,829 and the Nifty fell 0.12 percent at...
MedPlus Health faces near-term struggles, long-term gains possible, says Nomura
CNBC Awaaz· 4 hours agoMedPlus' operating EBITDA margin has fallen by 150 basis points between FY22 and FY24 primarily due to aggressive new store expansions, the company's entry into diagnostics, and the introduction of low-cost generics.